SCHEMBL2374202

SCHEMBL2374202

COC(=O)C(CN1CCCC1)N(Cc1ccc(-c2ccccn2)cc1)C(=O)/C=C/c1ccc(C(F)(F)F)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 4/20 0.40
NOS1 P29475 4/20 0.40
NOS2 P35228 4/20 0.40
TRPV1 Q8NER1 1/20 0.38
OPRK1 P41145 2/20 0.38
HDAC1 Q13547 1/20 0.37
HTR2A P28223 4/20 0.37
DRD2 P14416 4/20 0.37
DRD3 P35462 4/20 0.37
HTR1A P08908 3/20 0.37
TRPM8 Q7Z2W7 1/20 0.37
CHRM1 P11229 1/20 0.36
MCHR1 Q99705 1/20 0.36
HTR2C P28335 2/20 0.35
DRD4 P21917 1/20 0.35
KCNH2 Q12809 1/20 0.35
HRH3 Q9Y5N1 1/20 0.35
NR1H4 Q96RI1 1/20 0.35
MMP1 P03956 1/20 0.35
MMP9 P14780 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2374204 1.00 NOS3 (0.40) NOS3NOS1NOS2TRPV1OPRK1
SCHEMBL2374375 0.99 NOS3 (0.40) NOS3NOS1NOS2TRPV1OPRK1
SCHEMBL2374379 0.99 NOS3 (0.40) NOS3NOS1NOS2TRPV1OPRK1
SCHEMBL2375045 0.94 NOS3 (0.39) NOS3NOS1NOS2TRPV1HDAC1
SCHEMBL2375042 0.94 NOS3 (0.39) NOS3NOS1NOS2TRPV1HDAC1
SCHEMBL2376134 0.91 OPRK1 (0.40) TRPV1OPRK1HDAC1HTR2ATRPM8
SCHEMBL2376137 0.91 OPRK1 (0.40) TRPV1OPRK1HDAC1HTR2ATRPM8
SCHEMBL2375102 0.90 NOS3 (0.42) NOS3NOS1NOS2TRPV1HDAC1
SCHEMBL2375108 0.90 NOS3 (0.42) NOS3NOS1NOS2TRPV1HDAC1
SCHEMBL2375100 0.90 NOS3 (0.42) NOS3NOS1NOS2TRPV1HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110224210-A1 NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS ACTELION PHARMACEUTICALS LTD. (CH) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224210-A1 NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS CTSA, BECN1, HDAC6 NOS3 783/4885NOS1 996/4885NOS2 548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.